• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Severe chickenpox disease and seroprevalence in Sweden – implications for general vaccination
Chickenpox is the clinical manifestation of primary infection with varicella zoster virus (VZV) and a mild disease in the vast majority of cases. However, complications occur, primarily bacterial infections of vesicles, sometimes with deeper infection and sepsis, as well as neurological complications; e.g. encephalitis, meningitis, or classically acute cerebellitis with ataxia. Rare complications such as pneumonitis, hepatitis and haemorrhagic complications may occur (Gershon et al., 2018). There is even an increased risk of stroke in the time period 6 months after a chickenpox episode (Thomas et al., 2014).
Source: International Journal of Infectious Diseases - August 8, 2021 Category: Infectious Diseases Authors: K Widgren, L Persson Berg, A M örner, L Lindquist, A Tegnell, J Giesecke, M Studahl Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news